CCN3 and CCN3 peptides and analogs thereof for therapeutic use
View Patent ↗The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
1. A CCN3 peptide comprising a sequence selected from the group consisting of SEQ ID NOs: 36, 37, 38, 42, 49, 50, 53, 54, 55, 56, 57, 58, and 60.
2. A method for treating fatty liver disease, steatosis, liver fibrosis, liver cancer, hepatitis, inflammation, or neural inflammation in a subject comprising:
administering to the subject an effective amount of a CCN3 peptide comprising a sequence selected from the group consisting of SEQ ID Nos: 36-38, 40, 42, 49-50, 53-58, 60, and combinations thereof.
3. The method of claim 2 wherein the step of administering comprises delivering through a route of administration selected from the group consisting of intravenous, intramuscular, nasal, topical, vaginal, anal, transdermal, inhalation, oral, buccal, intraperitoneal, intrathecal, intraosseous and combinations thereof.
4. The method of claim 3 wherein the transdermal route of administration is transdermal patch or transdermal electrophoresis.
5. The method of claim 2 further comprising administration of a carrier molecule.
6. The method of claim 5 wherein the carrier molecule is selected from the group consisting of: polyethylene glycol (PEG), glycol groups, proteins, and serum proteins.
7. The method of claim 2 , wherein the method further comprises administering a stem cell solution.